NCT05583669已完成1 期
A Phase 1, Subject- and Investigator-Blinded, Sponsor-Unblinded, Placebo-Controlled, Randomized, Sequential Cohort Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Number of Participants with Any Treatment-emergent Adverse Events Following Administration of DS-2325a
研究概览
简要总结
Netherton syndrome (NS) is a rare autosomal recessive disease and no systemic treatment or standard of care currently exists for patients with NS. DS-2325a, a specific and potent inhibitor of kallikrein 5, is expected to treat NS by replacing a defective gene.
详细描述
This study for DS-2325a will evaluate the safety, tolerability, and pharmacokinetics of multiple ascending doses of DS-2325a in healthy participants. DS-2325a will be evaluated after subcutaneous (SC) injections.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Must be able to understand a written informed consent, which must be obtained prior to initiation of study procedures.
- •Must be willing and able to comply with all study requirements.
- •Healthy males or non-pregnant, non-lactating healthy females.
- •Aged 18 to 50 years of age (inclusive) at the time of signing informed consent.
- •BMI of 18.0 kg/m^2 to 30.0 kg/m^2 (inclusive) as measured at Screening.
- •Women of childbearing potential who are sexually active with a male partner must practice effective contraception during the study treatment period and for 90 days after last IMP administration. They must agree to use 2 different means of nonhormonal contraceptive methods.
- •Women of non-childbearing potential must be either surgically sterile or in menopausal state confirmed as follows: 1 year of spontaneous amenorrhea without an alternative medical cause and a serum follicle stimulating hormone (FSH) level ≥40 mIU/mL.
- •Male participants who are sexually active with a female partner of childbearing potential must use, with their partner, a condom plus an approved method of highly effective contraception from the time of informed consent until 90 days after last IMP administration.
- •Women should not donate eggs and men should not donate sperm during the study treatment period and for at least 90 days after last IMP administration.
- •All female participants must have a negative serum pregnancy test at Screening and Admission (Day -2).
排除标准
- •History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, metabolic, endocrine, immunologic, infectious, dermatologic, neurologic, oncologic, psychological, psychiatric, ophthalmologic, or gastrointestinal disease (except cholecystectomy), as judged by the Investigator.
- •History or presence of chronic lung or respiratory disease, including clinically significant asthma (as judged by the Investigator) and chronic obstructive pulmonary disease (COPD).
- •History, or presence in the average of triplicate ECGs at Screening and Admission (Day -2).
- •Laboratory results (serum chemistry, hematology, coagulation, and urinalysis) outside the normal range, if considered clinically significant by the Investigator at Screening or Admission (Day -2).
- •Creatinine clearance (CrCl) <80 mL/mina t Screening.
- •History or presence of any other clinically significant condition, including laboratory abnormality, that in the opinion of the Investigator, would jeopardize the safety of the participant, obtaining informed consent, compliance to the study procedures, or the validity of the study results.
研究组 & 干预措施
DS-2325a SC
Experimental
Participants who will be randomized to receive DS-2325a as a fixed dose subcutaneous (SC) injection (starting dose 300 mg).
干预措施: DS-2325a (Drug)
Placebo SC
Experimental
Participants who will be randomized to receive placebo as a subcutaneous (SC) injection.
干预措施: Placebo (Drug)
结局指标
主要结局
Number of Participants with Any Treatment-emergent Adverse Events Following Administration of DS-2325a
时间窗: Screening (Day -28 to -3) pre-dose up to Day 78 post-dose
Treatment-emergent adverse events (TEAEs) are defined as new adverse events (AEs) that occur after the dose of study drug or as AEs that were present prior to the dose of study drug but which worsened in severity after the start of study drug.
次要结局
- Pharmacokinetic Parameter Average Concentration (Cavg)(Day 1: pre-dose & 4, 8, 24, 72, 96, 120, 144 hours (hr) post-dose; Day 8 & 14: pre-dose; Day 22: pre-dose & 4, 8, 24, 48, 72, 96, 120, 144, 168 hr post-dose; Day 36, 43, 57, & 78)
- Pharmacokinetic Parameter Elimination Rate Constant Associated With the Terminal Phase (Kel)(Day 1: pre-dose & 4, 8, 24, 72, 96, 120, 144 hours (hr) post-dose; Day 8 & 14: pre-dose; Day 22: pre-dose & 4, 8, 24, 48, 72, 96, 120, 144, 168 hr post-dose; Day 36, 43, 57, & 78)
- Pharmacokinetic Parameter Drug Accumulation Ratio for AUCtau and Cmax (Rac)(Day 1: pre-dose & 4, 8, 24, 72, 96, 120, 144 hours (hr) post-dose; Day 8 & 14: pre-dose; Day 22: pre-dose & 4, 8, 24, 48, 72, 96, 120, 144, 168 hr post-dose; Day 36, 43, 57, & 78)
- Pharmacokinetic Parameter Area Under the Concentration Curve (AUCtau)(Day 1: pre-dose & 4, 8, 24, 72, 96, 120, 144 hours (hr) post-dose; Day 8 & 14: pre-dose; Day 22: pre-dose & 4, 8, 24, 48, 72, 96, 120, 144, 168 hr post-dose; Day 36, 43, 57, & 78)
- Pharmacokinetic Parameter Maximum Concentration (Cmax)(Day 1: pre-dose & 4, 8, 24, 72, 96, 120, 144 hours (hr) post-dose; Day 8 & 14: pre-dose; Day 22: pre-dose & 4, 8, 24, 48, 72, 96, 120, 144, 168 hr post-dose; Day 36, 43, 57, & 78)
- Pharmacokinetic Parameter Time to Maximum Concentration (Tmax)(Day 1: pre-dose & 4, 8, 24, 72, 96, 120, 144 hours (hr) post-dose; Day 8 & 14: pre-dose; Day 22: pre-dose & 4, 8, 24, 48, 72, 96, 120, 144, 168 hr post-dose; Day 36, 43, 57, & 78)
- Pharmacokinetic Parameter Terminal Elimination Half-life (T1/2)(Day 1: pre-dose & 4, 8, 24, 72, 96, 120, 144 hours (hr) post-dose; Day 8 & 14: pre-dose; Day 22: pre-dose & 4, 8, 24, 48, 72, 96, 120, 144, 168 hr post-dose; Day 36, 43, 57, & 78)
- Number of Participants Who Are Anti-Drug Antibody (ADA)-Positive (Baseline and Post-Baseline)(Day 1: pre-dose and Days 15, 22, 36, 57, and 78)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy SubjectsNetherton SyndromeNCT05388903Daiichi Sankyo64
终止
1 期
A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton SyndromeNetherton SyndromeNCT05979831Daiichi Sankyo9
招募中
不适用
Hereditary sensory neuropathy type 1 (HSN1) treatment trial.ACTRN12619000561189Concord Repatriation General Hospital20
尚未招募
不适用
Single cell analysis in Netherton syndromeComel-Netherton Syndrome10014982Netherton SyndromeNL-OMON53598Erasmus MC, Universitair Medisch Centrum Rotterdam12
Unknown
1 期
Gene Therapy for Netherton SyndromeNetherton SyndromeNCT01545323Great Ormond Street Hospital for Children NHS Foundation Trust5